Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBOVAC3DRC
NCT04186000Phase 2Completed
- Sponsor
- University of Antwerp
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by University of Antwerp. Started Dec 2019; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04186000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186000.